Вчера вышла совместная работа AMD Silo AI и AstraZeneca
From Benchmark to Bench: Can Agents Survive Real-World Drug Discovery?🔥
https://arxiv.org/abs/2610.06411
From Benchmark to Bench: Can Agents Survive Real-World Drug Discovery?🔥
https://arxiv.org/abs/2610.06411
We developed MAGI, an open modular agent that authors objectives, launches and monitors optimization, interprets structure-activity relationships, and revises its strategy accordingly. MAGI generates molecules either directly through the LLM or by delegating to REINVENT 4, with scoring services interchangeable behind a common contract. We tested it across nine retrospective lead-optimization campaigns from three pharmaceutical companies, replayed under fixed temporal cutoffs. Both routes produced valid structures: LLM proposals stayed closer to local chemistry and reached comparable or higher primary activity in fewer operations, whereas REINVENT explored broader chemical space.
Whether a campaign met its objective depended on the predictive models, not on the generation route: attainment followed model accuracy on the chemistry proposed, dropping once that chemistry moved outside the model's applicability domain.
Separately, a blinded evaluation asked whether the MAGI's output could pass as expert work: chemists were not able to discriminate agentic proposals from held-out compounds, and judged the SAR reasoning broadly plausible yet incomplete. Together, these results position MAGI as a coordination layer pluggable into existing computational chemistry workflows. The ceiling on real projects, however, remains currently set by scorer applicability rather than by tool orchestration.